We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Xenon Stock Rises 12% in the Past Month on Pipeline Progress
Read MoreHide Full Article
Key Takeaways
XENE stock gained 11.9% in a month, driven by azetukalner progress and optimism ahead of clinical milestones.
Xenon held $1.15 billion in cash, cash equivalents and marketable securities as of Sept. 30, 2026.
Xenon reported encouraging phase I results for its non-opioid pain candidates, XEN1701 and XEN1120.
Shares of Xenon Pharmaceuticals (XENE - Free Report) have gained 11.9% over the past month compared with the industry’s 6.2% growth, supported by progress in its lead epilepsy candidate, azetukalner, encouraging early-stage results from its non-opioid pain programs, growing investor optimism ahead of key clinical milestones and a strong financial position.
Xenon's better-than-expected third-quarter 2026 results, reported last week, may have further supported the stock. The company reported a loss of $1.11 per share, narrower than the Zacks Consensus Estimate of a loss of $1.14.
Image Source: Zacks Investment Research
XENE’s Progress With Lead Drug Candidate Azetukalner
Investor optimism appears to be supported by progress in Xenon's lead candidate, azetukalner, which is being developed for epilepsy and neuropsychiatric disorders.
The company submitted a new drug application (NDA) to the FDA in September, seeking approval for azetukalner for the treatment of focal onset seizures (FOS) in epilepsy. This represents an important step toward the potential commercialization of the candidate in the United States. If approved, the company will gain its first commercial product.
Xenon continues to expand the azetukalner epilepsy program. While the X-TOLE2 study data were announced in March, the identical phase III X-TOLE3 study is currently enrolling patients and is intended to support potential regulatory submissions for azetukalner for FOS in ex-U.S. jurisdictions. Patient enrollment outside Japan is expected to be completed later in the year. The company is evaluating azetukalner for primary generalized tonic-clonic seizures in a phase III X-ACKT study. Patient enrollment is ongoing. The company plans to initiate the phase IIIb/IV X-FIRST study in the first quarter of 2027 to evaluate azetukalner as a first add-on antiseizure treatment.
Investors are also looking forward to upcoming clinical developments for azetukalner in psychiatric disorders.
The company has completed approximately 80% of the planned patient enrollment in the phase III X-NOVA2 study evaluating the candidate in major depressive disorder (MDD). Top-line results are expected by the end of this year, earlier than the previously anticipated first-quarter 2027 timeline. Positive results could strengthen the drug's potential beyond epilepsy and expand its addressable market.
However, the program faces some uncertainty following Xenon's decision in September 2026 to voluntarily pause enrollment of new patients across its ongoing phase III psychiatric studies after reviewing certain neuropsychiatric adverse events. The studies include X-NOVA2 and X-NOVA3 in MDD and X-CEED in bipolar depression I or II. Patients already enrolled will continue participating in the studies while the company evaluates potential dose modifications and other risk-mitigation measures.
Xenon Reports Positive Clinical Data From Pain Programs
One of the key developments supporting investor sentiment was Xenon's announcement in late October of positive phase I results for its investigational non-opioid pain candidates, XEN1701 and XEN1120.
Both candidates demonstrated encouraging safety and pharmacokinetic profiles in early-stage studies. XEN1701 achieved its targeted receptor occupancy, while XEN1120 reached drug exposure levels expected to support pain relief based on preclinical modeling. Xenon plans to initiate phase II proof-of-concept studies for both candidates in the first half of 2027. These developments strengthen Xenon's early-stage pipeline and highlight its potential to expand into the pain management market beyond its existing focus on epilepsy and psychiatric disorders.
XENE’s Strong Cash Position Supports Pipeline Development
Xenon's solid financial position may have further boosted investor confidence. As of Sept. 30, 2026, the company held approximately $1.15 billion in cash, cash equivalents and marketable securities. Management expects its existing cash resources to fund operations into 2029. Its strong liquidity position provides financial flexibility to advance its clinical programs and prepare for the potential commercialization of azetukalner.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.06 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.21. AMRX’s shares have jumped 68.5% year to date.
Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.
Over the past 30 days, loss per share estimates for AC Immune have narrowed from 60 cents to 54 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from 17 cents to 43 cents. ACIU’s shares have declined 33.4% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 37.79%.
Over the past 30 days, loss per share estimates for Adaptive Biotechnologies have narrowed from 55 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have also improved from 17 cents to 3 cents. ADPT’s shares have surged 71.6% year to date.
Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 53.62%.
Image: Bigstock
Xenon Stock Rises 12% in the Past Month on Pipeline Progress
Key Takeaways
Shares of Xenon Pharmaceuticals (XENE - Free Report) have gained 11.9% over the past month compared with the industry’s 6.2% growth, supported by progress in its lead epilepsy candidate, azetukalner, encouraging early-stage results from its non-opioid pain programs, growing investor optimism ahead of key clinical milestones and a strong financial position.
Xenon's better-than-expected third-quarter 2026 results, reported last week, may have further supported the stock. The company reported a loss of $1.11 per share, narrower than the Zacks Consensus Estimate of a loss of $1.14.
Image Source: Zacks Investment Research
XENE’s Progress With Lead Drug Candidate Azetukalner
Investor optimism appears to be supported by progress in Xenon's lead candidate, azetukalner, which is being developed for epilepsy and neuropsychiatric disorders.
The company submitted a new drug application (NDA) to the FDA in September, seeking approval for azetukalner for the treatment of focal onset seizures (FOS) in epilepsy. This represents an important step toward the potential commercialization of the candidate in the United States. If approved, the company will gain its first commercial product.
Xenon continues to expand the azetukalner epilepsy program. While the X-TOLE2 study data were announced in March, the identical phase III X-TOLE3 study is currently enrolling patients and is intended to support potential regulatory submissions for azetukalner for FOS in ex-U.S. jurisdictions. Patient enrollment outside Japan is expected to be completed later in the year. The company is evaluating azetukalner for primary generalized tonic-clonic seizures in a phase III X-ACKT study. Patient enrollment is ongoing. The company plans to initiate the phase IIIb/IV X-FIRST study in the first quarter of 2027 to evaluate azetukalner as a first add-on antiseizure treatment.
Investors are also looking forward to upcoming clinical developments for azetukalner in psychiatric disorders.
The company has completed approximately 80% of the planned patient enrollment in the phase III X-NOVA2 study evaluating the candidate in major depressive disorder (MDD). Top-line results are expected by the end of this year, earlier than the previously anticipated first-quarter 2027 timeline. Positive results could strengthen the drug's potential beyond epilepsy and expand its addressable market.
However, the program faces some uncertainty following Xenon's decision in September 2026 to voluntarily pause enrollment of new patients across its ongoing phase III psychiatric studies after reviewing certain neuropsychiatric adverse events. The studies include X-NOVA2 and X-NOVA3 in MDD and X-CEED in bipolar depression I or II. Patients already enrolled will continue participating in the studies while the company evaluates potential dose modifications and other risk-mitigation measures.
Xenon Reports Positive Clinical Data From Pain Programs
One of the key developments supporting investor sentiment was Xenon's announcement in late October of positive phase I results for its investigational non-opioid pain candidates, XEN1701 and XEN1120.
Both candidates demonstrated encouraging safety and pharmacokinetic profiles in early-stage studies. XEN1701 achieved its targeted receptor occupancy, while XEN1120 reached drug exposure levels expected to support pain relief based on preclinical modeling. Xenon plans to initiate phase II proof-of-concept studies for both candidates in the first half of 2027. These developments strengthen Xenon's early-stage pipeline and highlight its potential to expand into the pain management market beyond its existing focus on epilepsy and psychiatric disorders.
XENE’s Strong Cash Position Supports Pipeline Development
Xenon's solid financial position may have further boosted investor confidence. As of Sept. 30, 2026, the company held approximately $1.15 billion in cash, cash equivalents and marketable securities. Management expects its existing cash resources to fund operations into 2029. Its strong liquidity position provides financial flexibility to advance its clinical programs and prepare for the potential commercialization of azetukalner.
Xenon Pharmaceuticals Inc. Price and Consensus
Xenon Pharmaceuticals Inc. price-consensus-chart | Xenon Pharmaceuticals Inc. Quote
XENE's Zacks Rank & Stocks to Consider
Xenon currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals (AMRX - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and AC Immune (ACIU - Free Report) and Adaptive Biotechnologies (ADPT - Free Report) , carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.06 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.21. AMRX’s shares have jumped 68.5% year to date.
Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.
Over the past 30 days, loss per share estimates for AC Immune have narrowed from 60 cents to 54 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from 17 cents to 43 cents. ACIU’s shares have declined 33.4% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 37.79%.
Over the past 30 days, loss per share estimates for Adaptive Biotechnologies have narrowed from 55 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have also improved from 17 cents to 3 cents. ADPT’s shares have surged 71.6% year to date.
Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 53.62%.